يعرض 1 - 10 نتائج من 53 نتيجة بحث عن '"Solomon, BJ"', وقت الاستعلام: 0.69s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    العلاقة: Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., de Braud, F., Solomon, B. J., Tan, D. S. -W., Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S. S., Puri, T., Bence Lin, A., Loong, H. & Besse, B. (2023). Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. JOURNAL OF CLINICAL ONCOLOGY, 41 (2), pp.385-+. https://doi.org/10.1200/JCO.22.00393Test.; http://hdl.handle.net/11343/320038Test

  4. 4
    دورية أكاديمية

    العلاقة: Posner, A., Prall, O. W., Sivakumaran, T., Etemadamoghadam, D., Thio, N., Pattison, A., Balachander, S., Fisher, K., Webb, S., Wood, C., DeFazio, A., Wilcken, N., Gao, B., Karapetis, C. S., Singh, M., Collins, I. M., Richardson, G., Steer, C., Warren, M. ,. Tothill, R. W. (2023). A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. JOURNAL OF PATHOLOGY, 259 (1), pp.81-92. https://doi.org/10.1002/path.6022Test.; http://hdl.handle.net/11343/335180Test

  5. 5
    دورية أكاديمية

    العلاقة: NHMRC/1175929; NHMRC/1173450; pii: S1368-8375(24)00005-8; Young, R. J., Angel, C., Bressel, M., Pizzolla, A., Thai, A. A., Porceddu, S. V., Liu, H., Idrizi, R., Metta, J., Lim, A. M., Solomon, B. J. & Rischin, D. (2024). Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer. ORAL ONCOLOGY, 150, https://doi.org/10.1016/j.oraloncology.2024.106687Test.; http://hdl.handle.net/11343/343904Test

  6. 6
    دورية أكاديمية

    العلاقة: Solomon, B. J., Bauer, T. M., Ou, S. -H. I., Liu, G., Hayashi, H., Bearz, A., Penkov, K., Wu, Y. -L., Arrieta, O., Jassem, J., Calella, A. M., Peltz, G., Polli, A., Thurm, H. & Mok, T. (2022). Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. JOURNAL OF CLINICAL ONCOLOGY, 40 (31), pp.3593-+. https://doi.org/10.1200/JCO.21.02278Test.; http://hdl.handle.net/11343/320384Test

  7. 7
    دورية أكاديمية

    العلاقة: pii: S1525-7304(22)00165-6; Ahn, M. -J., Mendoza, M. J. L., Pavlakis, N., Kato, T., Soo, R. A., Kim, D. -W., Liam, C. K., Hsia, T. -C., Lee, C. K., Reungwetwattana, T., Geater, S., Chan, O. S. H., Prasongsook, N., Solomon, B. J., Nguyen, T. T. H., Kozuki, T., Yang, J. C. -H., Wu, Y. -L., Kam, T. S. ,. Yatabe, Y. (2022). Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. CLINICAL LUNG CANCER, 23 (8), pp.670-685. https://doi.org/10.1016/j.cllc.2022.07.012Test.; http://hdl.handle.net/11343/322117Test

  8. 8
    دورية أكاديمية

    العلاقة: pii: S2059-7029(22)00019-9; Solomon, B. J., Loong, H. H., Summers, Y., Thomas, Z. M., French, P., Lin, B. K., Sashegyi, A., Wolf, J., Yang, J. C. -H. & Drilon, A. (2022). Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO OPEN, 7 (2), https://doi.org/10.1016/j.esmoop.2022.100398Test.; http://hdl.handle.net/11343/305824Test

  9. 9
    دورية أكاديمية

    العلاقة: pii: S1556-0864(21)03417-1; Ou, S. -H., Solomon, B. J., Shaw, A. T., Gadgeel, S. M., Besse, B., Soo, R. A., Abbattista, A., Toffalorio, F., Wiltshire, R. & Bearz, A. (2022). Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. JOURNAL OF THORACIC ONCOLOGY, 17 (4), pp.568-577. https://doi.org/10.1016/j.jtho.2021.12.011Test.; http://hdl.handle.net/11343/308994Test

  10. 10
    دورية أكاديمية

    العلاقة: pii: S0169-5002(22)00453-6; Soo, R. A., Tan, E. H., Hayashi, H., Seto, T., Lin, C. -C., Ou, S. -H. I., Kim, D. -W., Liu, G., Abbattista, A., Martini, J. -F., Martini, F., Wong, C. H., Toffalorio, F. & Solomon, B. J. (2022). Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. LUNG CANCER, 169, pp.67-76. https://doi.org/10.1016/j.lungcan.2022.05.012Test.; http://hdl.handle.net/11343/322261Test